BBIO — BridgeBio Pharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapMomentum Trap

Annual cashflow statement for BridgeBio Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-586	-485	-653	-543	-733
Depreciation
Non-Cash Items	83.7	24	114	-15.5	333
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-1.06	34.3	5.06	32	-51.1
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	-498	-419	-528	-521	-446
Capital Expenditures	-13.2	-6.32	-1.31	-8.91	-9.59
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-188	459	55.3	69.7	-14.9
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-201	453	54	60.8	-24.5
Financing Cash Flow Items	-164	-0.724	-7.68	-7.53	257
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	736	-13.1	452	748	359
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	37.7	20.5	-22.2	289	-111